IMCR (Immunocore Holdings) COGS-to-Revenue : 0.01 (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Immunocore Holdings COGS-to-Revenue?

Immunocore Holdings's Cost of Goods Sold for the three months ended in Mar. 2025 was $0.8 Mil. Its Revenue for the three months ended in Mar. 2025 was $93.9 Mil.

Immunocore Holdings's COGS to Revenue for the three months ended in Mar. 2025 was 0.01.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Immunocore Holdings's Gross Margin % for the three months ended in Mar. 2025 was 99.11%.

Immunocore Holdings COGS-to-Revenue Historical Data

The historical data trend for Immunocore Holdings's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunocore Holdings COGS-to-Revenue Chart

Immunocore Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.01

Immunocore Holdings Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
COGS-to-Revenue	Get a 7-Day Free Trial															-	0.02	0.01	-	0.01

Immunocore Holdings COGS-to-Revenue Calculation

Immunocore Holdings's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	2.731	/	310.202
	=	0.01

Immunocore Holdings's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.831	/	93.881
	=	0.01

Immunocore Holdings (NAS:IMCR) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Immunocore Holdings's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0.831 / 93.881
	=	99.11 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Immunocore Holdings COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Immunocore Holdings's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunocore Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunocore Holdings PLC (NAS:IMCR) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

6YG:Germany

Address

92 Park Drive, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY

Website

https://www.immunocore.com

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.